Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC …

Dec 23, 2024 · Rhythm Pharmaceuticals Stock Down 0.1 %. Shares of NASDAQ:RYTM traded down $0.08 during trading on Monday, hitting $56.04. 904,976 shares of the stock traded …

$0.08
OFF

Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed At HC …

1 week from now

Dec 23, 2024 · Rhythm Pharmaceuticals Stock Down 0.1 %. Shares of NASDAQ:RYTM traded down $0.08 during trading on Monday, hitting $56.04. 904,976 shares of the stock traded …

marketbeat.com

$80.00
OFF

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold By …

1 week from now

4 days ago · Jefferies Financial Group began coverage on Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a "buy" rating and a $80.00 price objective for the …

marketbeat.com

$69.00
OFF

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average …

1 week from now

Dec 24, 2024 · HC Wainwright reaffirmed a “buy” rating and issued a $69.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday. Oppenheimer started …

etfdailynews.com

$59.92
OFF

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given “Buy” Rating At …

1 week from now

Nov 26, 2024 · RYTM stock opened at $59.92 on Monday. The business’s fifty day moving average price is $53.35 and its 200 day moving average price is $47.28. Rhythm …

etfdailynews.com

$69.00
OFF

Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM

1 week from now

Dec 19, 2024 · HC Wainwright reiterated a "buy" rating and set a $69.00 target price on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 4th. Guggenheim …

marketbeat.com

$77.00
OFF

Buy Rating Reaffirmed For Rhythm Pharmaceuticals Amid Strong …

1 week from now

Aug 7, 2024 · Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) yesterday and set a price target of $77.00.. …

businessinsider.com

$64.00
OFF

Buy Rating Upheld For Rhythm Pharmaceuticals Amid Growth And …

1 week from now

Oct 7, 2024 · In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price target of $64.00. …

businessinsider.com

$69.00
OFF

Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Unusually-High

1 week from now

Dec 23, 2024 · HC Wainwright reissued a "buy" rating and issued a $69.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday. Needham & Company LLC …

marketbeat.com

$75.00
OFF

Jefferies Financial Group Begins Coverage On Rhythm …

1 week from now

Jan 2, 2025 · JMP Securities reaffirmed a "market outperform" rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Finally, …

marketbeat.com

$59
OFF

What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals

1 week from now

Sep 18, 2024 · Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $59.5, accompanied by a high estimate of $64.00 …

nasdaq.com

$55.85
OFF

JMP Securities Reaffirms Market Outperform Rating For Rhythm ...

1 week from now

Dec 25, 2024 · Shares of RYTM stock opened at $55.85 on Monday. The company has a market cap of $3.43 billion, a P/E ratio of -12.90 and a beta of 2.14. The stock’s 50-day moving …

etfdailynews.com

$69.00
OFF

Rhythm Pharmaceuticals (RYTM) News Today - MarketBeat

1 week from now

Jan 10, 2025 · Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC Wainwright HC Wainwright restated a "buy" rating and set a $69.00 price target on shares of Rhythm …

marketbeat.com

$65.00
OFF

Rhythm Pharmaceuticals: Strong Financial Performance And …

1 week from now

Nov 5, 2024 · In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price target of $65.00. …

businessinsider.com

$70.00
OFF

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus ...

1 week from now

4 days ago · Guggenheim initiated coverage on Rhythm Pharmaceuticals in a research report on Monday, October 21st. They set a "buy" rating and a $70.00 price objective on the stock. …

marketbeat.com

FAQs about Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC … Coupon?

Is Rhythm Pharmaceuticals (Rytm) a good stock to buy?

Rhythm Pharmaceuticals (RYTM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $69.00 price target. ...

Can HC Wainwright buy Rhythm Pharmaceuticals?

HC Wainwright reaffirmed a “buy” rating and issued a $69.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday. Oppenheimer started coverage on Rhythm Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $76.00 target price for the company. ...

What is the 12-month price forecast for Rhythm Pharmaceuticals (Rytm)?

The 12-month stock price forecast is $63.7, which is an increase of 12.33% from the latest price. BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar... ...

What is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. In the past 90 days, it has been the subject of 3 research reports. ...

Why has Whitney Ijem rated Rhythm Pharmaceuticals a buy?

Whitney Ijem has given his Buy rating due to a combination of factors including Rhythm Pharmaceuticals’ solid performance in the second quarter of 2024 and the company’s promising pipeline. The firm’s revenue for the quarter met expectations, while earnings exceeded forecasts, partly because of a significant one-time financial gain. ...

Should you buy Rhythm Pharmaceuticals?

Coupled with near-term catalysts such as the completion of Phase 3 trial enrollments that could significantly broaden the addressable market, and upcoming regulatory milestones, Rhythm Pharmaceuticals presents a compelling growth narrative that underpins Wolleben’s Buy recommendation. ...